Page 14 - Pharma Sector

Anti-infective medicine sales slowing down: Pharmaceutical industry

Focus on chronic therapies and ban on some combination drugs among reasons

This pharma entrepreneur became a billionaire by pushing opiods on patients

The sales strategy was based on an 'eat-what-you-kill philosophy,' a former chief executive officer of the firm said. 'When you sell a lot, you make a lot.'

Booster dose for pharma as Govt okays refund on foreign plant inspection

Commerce Ministry raises cap to Rs 2 crore a year per drug exporter from Rs 50 lakh under MAI scheme; 50% of costs incurred towards statutory compliance to be borne by firm

Acute therapy segments pull down domestic pharma sales growth to 6% in Nov

While Indian companies grew 6.2 per cent for the month, multinational firms grew slightly faster at 6.8 per cent for the same period

Pharma sector likely to post higher Q2 margins on weak rupee: India Ratings

It expects that the positive currency impact to continue and the rupee to average Rs 69.79 per US dollar in FY19, a depreciation of 8.3 per cent

Dr Reddy's sells Hyderabad API unit to Neopharma JV in lump sum deal

Therapiva Private Limited is a joint venture between Omnicare Drugs India Private Limited, a subsidiary of Neopharma LLC, Abu Dhabi and Laxai Life Sciences Private Limited

Pharma sector back in focus; outlook positive but bets likely to be risky

Things are further improving for companies focussed on the US. Many large generic US players are moving out of certain drugs, which creates opportunities for the Indian players

Till May 2018, govt imposed Rs 60 bn fine on drug firms for overcharging

In a separate reply, minister of state for chemicals and fertilisers said exports of generic drugs in 2017-18 stood at $12.9 billion

Is pharma sector worth the bet?

Historically, it has been a huge outperformer over two decades

As trade war with US intensifies, China opens door to Indian pharma

Swift regulatory approvals in China would allow Indian companies to boost revenue at a time when pricing scrutiny and regulatory troubles have hurt US sales

Pharma sector seen posting moderate growth in FY19 on slow US market

The domestic pharmaceutical sector is likely to register a moderate, single-digit revenue growth in the current fiscal year, on slowing US market growth, increased competition and regulatory overhang, a report said. Consolidation of supply chain in the US market resulting in pricing pressures along with sustained investments in research and development (R&D) will also have an impact on profitability of Indian pharmaceutical companies, Icra said in its report. "The growth trajectory for Indian pharmaceutical industry is likely to be moderate, in single digit, on slowing growth from the US given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion in low double digit, generic adoption reaching saturation levels and regulatory overhang along with base effect catching up," the report said. The rating agency said the revenue growth from the US has come down from 14.4 per cent in FY16 to 4 per cent in FY17

Now, one-fourth of Indian pharma market to be under price control

Around 17% of the Rs 1.2-trillion Indian pharma market is now under price control

Multinational drug makers shine as domestic pharma market grows 10%

Overcoming of pricing controls via line extensions aiding growth

Import of medical devices from US on the rise; here's all you need to know

Import in the category rose from $1.35 bn in 2016-17 to $1.52 bn in 2017-18, a 12 per cent rise

What ails India's pharma sector? Brand launches last year lowest since 2013

In 2017, there were only 3,932 pharma brand launches, of which 386 were in the dermatology segment alone

Govt stalls plan to cut drug prices after pushback from pharma companies

The Indian Pharmaceutical Alliance and other industry bodies argued these changes would increase drug prices, cost jobs and hamper innovation

Pharma sector earnings to remain flat on damp business in US, strong rupee

Edelweiss Securities expects the financial year 2017-18 is expected to be a 'challenging year'

Indian pharma companies under pressure on bourses, MNC peers fare better

Given the India focus, they will benefit more from domestic market growth, compared with Indian companies, which are currently facing pressure in their US businesses

Pharma weight in BSE to touch 5-year low

With drug makers Lupin and Cipla set to be replaced in the S&P BSE Sensex by IndusInd Bank and YES Bank, the weight of the pharmaceutical industry in the index would decline to a five-year low. The index, jointly owned by the BSE and the US-based S&P, is a free float, market-weighted stock index of 30 companies. "All over the world indices ride on successful stocks as these are made of weights by market capitalisation," said G Chokkalingam, founder and managing director, Equinomics Research & Advisory.On Friday, four drug makers together had a 4 per cent weight in the Sensex with Cipla and Lupin, respectively, weighing in at 0.9 per cent and 0.6 per cent. The other two drug makers, Sun Pharma and Dr Reddy's Laboratories, respectively, had weights of 1.7 per cent and 0.8 per cent. The BSE and S&P said on Friday that the Cipla and Lupin scrips would be replaced in the Sensex by December 18.This would bring down the pharmaceutical industry's weight in the Sensex to 2.5 ...

Pharma growth to pick up in 2nd half

Companies have been under pressure after weak Q2 results and regulatory headwinds